Genentech - A Member of the Roche Group

Alzheimer's Prevention Trial - About Genentech's Involvement

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history. Richard Schelller, Genentech's Executive Vice President of Research and Early Development, discusses Genentech's involvement in the trial.

You Might Also Be Interested In

Impacting a Unique Patient Population

Why the patient population of the prevention trial is so unique and how Alzheimer's has had an impact on their lives.

Science and significance of the trial

Richard Scheller discusses the background and significance of the study, as well as the theory behind crenezumab.

Feedback?

Tell us what you think about our company, products, or website.

“
The important thing in science is not so much to obtain new facts as to discover new ways of thinking about them.
” – William Lawrence Bragg
Connect with us